Aldaz Pablo, Garjón Javier, Beitia Guadalupe, Beltrán Idoya, Librero Julián, Ibáñez Berta, Arroyo Pilar, Ariz Ma José
Navarre Health Service, IdiSNA, Navarra Institute for Health Research, Spain.
Navarre Health Service, IdiSNA, Navarra Institute for Health Research, Spain.
Med Clin (Barc). 2021 Feb 12;156(3):107-111. doi: 10.1016/j.medcli.2020.02.006. Epub 2020 May 17.
To evaluate the association between use of benzodiazepines and incident dementia.
Analytical prospective nested case-control study for which the Spanish database for pharmacoepidemiological research in primary care (BIFAP) of the Spanish Agency of Medicines and Medical Devices (AEMPS) was used. A total of 15,212 subjects diagnosed with dementia of the Alzheimer type and 62,397 controls were identified. Exposure was retrieved retrospectively with a 3-year lag time before the index date. Adjusted odd ratios (OR) were calculated.
Benzodiazepines use increased the risk of suffering Alzheimer's disease (OR=1.05, 95% CI, 1.01-1.10). No statistical differences were shown between short-acting and long-acting drugs. The risk is more evident with longer exposure times.
There seems to be a weak association between benzodiazepine use and the development of dementia, the risk increases with greater exposure.
评估使用苯二氮䓬类药物与新发痴呆之间的关联。
采用分析性前瞻性巢式病例对照研究，使用西班牙药品和医疗器械局（AEMPS）的初级保健药物流行病学研究西班牙数据库（BIFAP）。共识别出15212例被诊断为阿尔茨海默病型痴呆的受试者和62397例对照。在索引日期前3年的滞后时间内回顾性检索暴露情况。计算调整后的比值比（OR）。
使用苯二氮䓬类药物会增加患阿尔茨海默病的风险（OR=1.05，95%CI，1.01-1.10）。短效和长效药物之间未显示出统计学差异。暴露时间越长，风险越明显。
苯二氮䓬类药物的使用与痴呆的发生之间似乎存在微弱关联，暴露时间越长，风险越高。
